

# Infographic




**NNHLA**

National Non-Hodgkin Lymphoma Audit

Summary of results for people diagnosed with Non-Hodgkin Lymphoma (NHL) in England (2022) and Wales (2023).

## Data completeness



## Diagnosis and staging

### Diagnoses per year

**England**  
15,433 diagnosed in 2022

**Wales**  
729 diagnosed in 2023

### Grade of lymphoma

**England 2022**  
high-grade 50 %, low-grade 49%, not classified 0.8%

**Wales 2023**  
high-grade 50%, low-grade 45%, not classified 5%

### MDT discussion within 4 weeks of diagnosis, where recorded

**England 2022** - 60.0%, (high-grade 65%, low-grade 54%)

No data on MDT discussion was provided for Wales

**69**  
years

**Mean age at diagnosis for both England & Wales**

### Emergency presentation

**England 2022** - 28%

Development work underway for Welsh data.



### Clinical Nurse Specialist (CNS) seen, where recorded

**England 2022** 83%  
**Wales 2023** 96%

40% data completeness for England 2022

## Treatment

### Systemic Anti-Cancer Therapy (SACT)

Percentage of people diagnosed with high grade lymphoma, who receive SACT within 62 days of referral

**England 2022**



**55%**

**Wales 2023**



**48%**

**33%**

### Timing of Radiotherapy delivery

Percentage of people diagnosed with high-grade lymphoma, who received radiotherapy within 8 weeks of end of first line SACT.

**England 2022**



End date for 1st line chemotherapy was not provided for Wales so this indicator could not be measured.

**2%**


### Trial Participation

Percentage of people with NHL who are recorded as having received an episode of care that was delivered as part of a clinical trial in **England 2022\***

\* Note 47% data missing. No data on trial participation for Wales was available

## Survival

### One-year survival outcomes



### Two-year survival outcomes\*

Not available for Wales due to insufficient follow up period

